• A$65 million royalty income from DAYBUE® (trofinetide) in 2025, up 15% from 2024
• 2025 profit after tax A$30 million
• A$510 million cumulative income earned from DAYBUE since launch in 2023

Neuren Pharmaceuticals Limited (ASX: NEU) announced financial results for 2025, reporting royalty income of A$65 million and profit after tax of A$30 million. The company achieved a critical milestone with the commencement of its Koala Phase 3 clinical trial of NNZ-2591 in Phelan-McDermid syndrome. Royalty income from DAYBUE® (trofinetide) was A$65 million, up 15% from 2024, and Neuren has now earned A$510 million in cumulative income from DAYBUE since its launch in 2023. Acadia Pharmaceuticals, Neuren's exclusive worldwide licensee for trofinetide, provided guidance for 2026 DAYBUE net sales of US$460-490 million, implying royalties to Neuren of A$70-77 million. Neuren also advanced NNZ-2591 for Pitt Hopkins syndrome and initiated development for hypoxic ischemic encephalopathy (HIE), partnering with Hope for HIE. The company's strong cash position of A$296 million at the end of 2025 supports the ongoing development programs and a new A$50 million on-market share buy-back.

Acadia has provided guidance for full-year net sales in 2026 of US$460-490 million. Assuming this guidance is met and an exchange rate range of 0.70-0.72, Neuren anticipates earning full-year royalties of A$70-77 million.